For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Ipamorelin: origin, structure and research history

Research Library › GHRH & Ghrelin-Receptor

Ipamorelin is a synthetic pentapeptide (five amino acids) designed to act at the growth hormone secretagogue receptor, the receptor whose natural ligand is ghrelin. It was described in 1998 by a Novo Nordisk team in Måløv, Denmark, as an offshoot of the GHRP-1 peptide series, and later studied by Helsinn Therapeutics. As of 22 Oct 2026 it is not approved in any country and sits on FDA’s Category 2 list for compounding.

Key facts

TypeSynthetic 5-amino-acid peptide (pentapeptide)
Derived fromGHRP-1 series, with its central Ala-Trp pair removed
First described1998, Novo Nordisk (Raun et al., European Journal of Endocrinology)
Developed byNovo Nordisk, Måløv, Denmark; later Helsinn Therapeutics
Designed targetGrowth hormone secretagogue (ghrelin) receptor on the pituitary
Regulatory status (Oct 2026)Not approved anywhere; FDA Category 2 (503B) since 2023; named on WADA 2026 list (S2)

Who developed it

Ipamorelin was developed at Novo Nordisk in Måløv, Denmark. The team, with K. Raun as first author, introduced it in 1998 under the title “Ipamorelin, the first selective growth hormone secretagogue” [1]. Helsinn Therapeutics later licensed the compound and took it into U.S. clinical trials [2][3]. AdisInsight lists Novo Nordisk as the originator and both companies as developers [2].

The name places it in the “-relin” family of growth hormone-releasing compounds, alongside sermorelin, tesamorelin and hexarelin.

What it was designed to target

Ipamorelin came from a series of peptides built on GHRP-1, one of the growth hormone-releasing peptides first made in the 1980s. The Novo team removed GHRP-1’s central alanine-tryptophan pair and arrived at a five-residue compound [1].

Like the GHRPs, ipamorelin is designed to bind the growth hormone secretagogue receptor (GHS-R) on the pituitary. When the receptor was first targeted, its natural ligand was unknown; in 1999 a Japanese team identified it as ghrelin, a hormone made in the stomach [4]. In the 1998 rat and pig studies, ipamorelin was characterized as selective: growth hormone release was not accompanied by rises in the stress hormones ACTH or cortisol, which set it apart from earlier GHRPs [1].

Why it was created

Earlier growth hormone-releasing peptides also raised ACTH and cortisol. Novo Nordisk set out to find a secretagogue as selective as GHRH itself [1]. Helsinn later investigated ipamorelin in a research program on postoperative ileus, the temporary stalling of gut motility after bowel surgery [3].

Research timeline

  • 1998: Novo Nordisk publishes ipamorelin [1].
  • 1999: Ghrelin is identified as the natural ligand of the receptor ipamorelin targets [4].
  • 2007: U.S. clinical trials in postoperative ileus begin [2].
  • 2011: Phase 2b enrollment begins in the U.S. [2].
  • 2014: A 117-patient phase 2 proof-of-concept study is published; it did not meet its primary endpoint [3].
  • 2015: AdisInsight’s profile reports no further development [2].
  • 2023: FDA places ipamorelin in Category 2 for outsourcing facilities [5].

Regulatory status as of October 2026

As of 22 Oct 2026, ipamorelin is not approved in any country we identified. In 2023 FDA placed it in Category 2 for 503B outsourcing facilities, citing a published report of serious adverse events, including a death, associated with intravenous use [5]. It was not among the 12 peptides FDA removed from Category 2 in April 2026 [6], and it was not one of the seven peptides FDA’s Pharmacy Compounding Advisory Committee voted on in July 2026 [7].

Ipamorelin is covered by the 2026 World Anti-Doping Agency Prohibited List under S2 as a growth hormone secretagogue, prohibited at all times [8].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who developed ipamorelin?

Ipamorelin was developed by Novo Nordisk in Måløv, Denmark, and first described in 1998 by Raun and colleagues. Helsinn Therapeutics later ran U.S. trials.

Is ipamorelin FDA approved?

No. As of 22 Oct 2026 ipamorelin is not approved anywhere, and FDA has listed it in Category 2 for outsourcing-facility compounding since 2023.

What receptor does ipamorelin target?

It is designed to bind the growth hormone secretagogue receptor (GHS-R), whose natural ligand is the stomach hormone ghrelin.

Why is ipamorelin called selective?

In 1998 animal studies, ipamorelin’s activity at the receptor was not accompanied by rises in ACTH or cortisol, unlike earlier GHRPs, so its developers called it the first selective growth hormone secretagogue.

Sources

  1. Raun K, Hansen BS, Johansen NL, et al. (Novo Nordisk A/S, Måløv, Denmark). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552. PMID 9849822. Link
  2. AdisInsight (Springer). Ipamorelin: drug profile (originator Novo Nordisk; developers Helsinn Therapeutics, Novo Nordisk). Last updated 12 Aug 2015. Link
  3. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527–1534. doi:10.1007/s00384-014-2030-8. PMID 25331030. Link
  4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402:656–660. doi:10.1038/45230. Link
  5. U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
  6. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
  7. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  8. World Anti-Doping Agency. 2026 Prohibited List, S2.2.4 (GHRH and its analogues; growth hormone secretagogues; GH-releasing peptides). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top